Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Some Thoughts in Summary
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(38)
•••
Comment by zwerp2000on Dec 28, 2022 10:48am
98 Views
Post# 35193490

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in SummaryNo! It's time to move on. This company is cooked. It's been cooked for years. They had years to push their pipeline forward but never did it. Why? Also, if xb3 was truly so valuable, how could the company not be able to secure financing or a partnership deal that would land them a decent upfront payment? How is the recent deal the best they can do with a "valuable" technology? Why has Chiesi and Prothena essentially done nothing with xb3? Yeah, prophetofabsurdity says it's the worse biotech market in years. Well, seveal years ago, biotechs were flying but this one did nothing. He is making up silly excuses. The truth is, xb3 is not very valuable at all. Shareholders have been sold a bag of bull about it. For years and years and years we heard how fabulous it is but nothing in the clinic? no progress? no real partnerships? come on! the comapny has nothing. The ceo is incompetent no doubt but she knew the company could not survive without doing this ridiculous deal. No one was interested in xb3

My question now is what did the ceo and other management do to earn a salary? it does not appear any progress was made in years. what did they do all day?? they essentially were paid to do nothing
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities